Patents Assigned to The United States of America as represented by the Secretary of the Department of Health and Human Services
-
Patent number: 11819020Abstract: Disclosed devices for recovering cryopreserved tissue can comprise a receptacle that receives a sealed, frozen tissue container containing cryopreserved tissue and cryopreservation media, with at least one recovery media chamber and a waste material chamber fluidly coupled to the tissue container receptacle. The recovery device can be inserted into a regulator apparatus that facilitates thawing and warming of the media and tissue, and regulation of the flow of recovery media through the tissue container to flush out the thawed cryopreservation media into the waste chamber. The regulator can identify the tissue based on an ID tag on the tissue container and automatically apply an appropriate algorithm for thawing, culturing, and maintaining the tissue in a viable state.Type: GrantFiled: January 31, 2018Date of Patent: November 21, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Vladimir Rouskov Khristov, Arvydas Miminishkis, Kapil Bharti
-
Publication number: 20230365633Abstract: The invention is directed to methods of treating or preventing a Rhabdoviridae virus infection in a mammal comprising administering griffithsin, or a fragment or mutant thereof, to the mammal.Type: ApplicationFiled: October 9, 2020Publication date: November 16, 2023Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, University of Louisville Research Foundation, Inc.Inventors: Nadia F. Gallardo-Romero, Barry R. O'Keefe, Kenneth E. Palmer
-
Publication number: 20230365568Abstract: Provided is a method of treating cancer, particularly cancers associated with an overexpression of polo-like kinase (Plk1), comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof in which ring A, X1, X2, X3, X4, X5, R2, R3, R4, n, bond a, and bond b are described herein. Exemplary compounds of formula (I) and pharmaceutically acceptable salts thereof, especially those that selectively inhibit the polo box domain of Plk1, also are provided.Type: ApplicationFiled: September 24, 2021Publication date: November 16, 2023Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Kyung S. Lee, Kenneth A. Jacobson, Celeste N. Alverez, Jung-Eun Park, Paola Oliva, Hobin Lee, Klara Pongorne Kirsch
-
Patent number: 11814674Abstract: Methods for the rapid amplification of extremely low quantity nucleic acids in a sample are provided. The disclosed methods are capable of amplifying less than 1 pg of DNA and/or RNA from a biological sample using a single tube and one-step or two-step preparation.Type: GrantFiled: February 1, 2019Date of Patent: November 14, 2023Assignee: The United States of America, as represented by the Secretary Department of Health and Human ServicesInventor: Fei Fan Ng
-
Patent number: 11814440Abstract: The present disclosure is directed to antibodies binding to Glypican 2 and methods of using such antibodies to treat cancers that express or overexpress the Glypican 2 antigen.Type: GrantFiled: November 8, 2016Date of Patent: November 14, 2023Assignees: The Children's Hospital of Philadelphia, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: John M. Maris, Kristopher R. Bosse, Dimiter Dimitrov, Zhongyu Zhu, Dontcho V. Jelev
-
Patent number: 11813316Abstract: The invention is directed to a more efficient lentiviral vector comprising a nucleic acid sequence encoding a human ?-globin protein or a human ?-globin protein, which is oriented from 5? to 3? relative to the lentiviral genome. The invention also provides a composition and method utilizing the lentiviral vector.Type: GrantFiled: December 17, 2019Date of Patent: November 14, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Naoya Uchida, John F. Tisdale
-
Patent number: 11806406Abstract: The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules.Type: GrantFiled: August 5, 2021Date of Patent: November 7, 2023Assignees: Aura Biosciences, Inc., The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Elisabet de los Pinos, John Todd Schiller, Rhonda C. Kines, John MacDougall
-
Patent number: 11806369Abstract: Methods are disclosed herein for treating glaucoma in a subject. In some embodiments, the methods increase retinal ganglion cell survival. The disclosed methods use exosomes and/or miRNA.Type: GrantFiled: June 7, 2021Date of Patent: November 7, 2023Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Stanislav Ivanovich Tomarev, Benjamin Frank John Martin Mead
-
Publication number: 20230346797Abstract: Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein.Type: ApplicationFiled: July 10, 2023Publication date: November 2, 2023Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Sanjay A. Desai, Ajay D. Pillai
-
Patent number: 11800983Abstract: Featured are methods, apparatus and devices for detecting a hematoma in tissue of a patient. In one aspect, such a method includes emitting near infrared light continuously into the tissue from a non-stationary near infrared light emitter and continuously monitoring the tissue using a non-stationary probe so as to continuously detect reflected light. The near infrared light is emitted at two distances from a brain of the patient, so the emitted light penetrates to two different depths. Such a method also includes applying a ratiometric analysis to the reflected light to distinguish a border between normal tissue and tissue exhibiting blood accumulation.Type: GrantFiled: August 30, 2017Date of Patent: October 31, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health & Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Jason D. Riley, Franck Amyot, Amir H. Gandjbakhche, James G. Smirniotopoulos, Eric Wassermann
-
Patent number: 11801153Abstract: Disclosed are powered gait assistance systems that include a controller, sensors, and a motor coupled to a patient's thigh and lower leg and operable to apply assistive torque to the patient's knee joint to assist the patient's volitional knee pivoting muscle output during selected stages of the patient's gait cycle, such that the assistive torque applied by the motor improves the patient's leg posture, muscle output, range of motion, and/or other parameters over the gait cycle. The sensors can include a torque sensor that measures torque applied by the motor, a knee angle sensor, a foot sensor that measures ground contact of the patient's foot, and/or other sensors. The controller can determine what stage of the patient's gait cycle the patient's leg is in based on sensor signals and cause the motor to apply corresponding assistive torque to the knee based on the gait cycle stage, sensor inputs, and known patient characteristics.Type: GrantFiled: July 31, 2017Date of Patent: October 31, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Thomas Bulea, Zachary Lerner, Diane Damiano, Andrew Gravunder
-
Patent number: 11793871Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. The vaccines comprise nanoparticles that display HA trimers from Group 2 influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to stabilized stem regions of Group 2 influenza virus HA proteins. The fusion proteins self-assemble to form the HA-displaying nanoparticles. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.Type: GrantFiled: May 11, 2022Date of Patent: October 24, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey C. Boyington, Barney S. Graham, John R. Mascola, Hadi M. Yassine, Kizzmekia S. Corbett, Syed M. Moin, Lingshu Wang, Masaru Kanekiyo
-
Patent number: 11795177Abstract: The disclosure provides compounds of Formula I, which may be useful as aldehyde dehydrogenase inhibitors and the pharmaceutically acceptable salts thereof. The variables, J, R4, G, Q, and ring A are defined herein. Aldehyde dehydrogenase inhibitors of Formula I are useful for treating a variety of conditions including cancer and inflammation. The disclosure includes methods for using compounds and salts of Formula I to treat colon cancer, pancreatic cancer, nasopharyngeal carcinoma, thyroid cancer, prostate cancer, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, hepatocellular carcinoma, leukemia, brain tumors breast cancer, atherosclerosis, ischaemic heart disease, acne vulgaris, asthma, autoimmune diseases, autoinflammatory diseases, chronic prostatitis, glomerulonephritis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis, and interstitial cystitis.Type: GrantFiled: February 28, 2022Date of Patent: October 24, 2023Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Shyh Ming Yang, David J. Maloney, Natalia Martinez, Adam Yasgar, Anton Simeonov
-
Patent number: 11795235Abstract: Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.Type: GrantFiled: September 18, 2018Date of Patent: October 24, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Ira H. Pastan, Junxia Wei, Masanori Onda, Tapan Bera, Mitchell Ho
-
Patent number: 11786589Abstract: A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.Type: GrantFiled: June 16, 2021Date of Patent: October 17, 2023Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Baoming Jiang, Roger I. Glass, Yuhuan Wang, Jon Gentsch
-
Patent number: 11786591Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.Type: GrantFiled: May 28, 2021Date of Patent: October 17, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Institute for Research in BiomedicineInventors: Peter Kwong, Michael Gordon Joyce, Baoshan Zhang, Yongping Yang, Peter Collins, Ursula Buchholz, Davide Corti, Antonio Lanzavecchia, Guillaume Stewart-Jones
-
Patent number: 11787764Abstract: Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems are disclosed. Certain heptamethine cyanines exhibit renal system specificity, while others exhibit biliary system specificity. The compounds may be used for diagnostic purposes and/or for visualization of renal or biliary systems during surgery.Type: GrantFiled: February 14, 2019Date of Patent: October 17, 2023Assignees: CHILDREN'S NATIONAL MEDICAL CENTER, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICESInventors: Martin John Schnermann, Peter C. W. Kim, Jaepyeong Cha, Roger Rauhauser Nani
-
Publication number: 20230321240Abstract: Disclosed are isolated or purified T cell receptors (TCRs) having antigenic specificity for human p53R273C or human p53Y220C. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: ApplicationFiled: September 2, 2021Publication date: October 12, 2023Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Sanghyun Kim, Nikolaos Zacharakis, Steven A. Rosenberg
-
Patent number: 11780931Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.Type: GrantFiled: December 14, 2021Date of Patent: October 10, 2023Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America, as represented by the Secretary, Department of Health and Human Services, The Regents of the University of CaliforniaInventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
-
Patent number: 11779570Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.Type: GrantFiled: June 28, 2022Date of Patent: October 10, 2023Assignees: FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Hengli Tang, Emily M. Lee, Wei Zheng, Ruili Huang, Miao Xu, Wenwei Huang, Khalida Shamim, Guoli Ming, Hongjun Song